Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia

Erik Imel, Munro Peacock, Pisit Pitukcheewanont, Howard J. Heller, Leanne M. Ward, Dorothy Shulman, Moustapha Kassem, Paula Rackoff, Mark Zimering, Alan Dalkin, Elaine Drobny, Giacomo Colussi, Joseph L. Shaker, Elizabeth H. Hoogendoorn, Siu Hui, Michael Econs

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Context: Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome of hypophosphatemia, decreased renal phosphate reabsorption, normal or low serum 1,25-dihydryxyvitamin-D concentration, myopathy, and osteomalacia. Fibroblast growth factor 23 (FGF23) is a phosphaturic protein overexpressed in tumors that cause TIO and is, at least partly, responsible for the manifestations of TIO. Objective: The objective of this study was to determine the sensitivity of FGF23 measurements in TIO. Design: FGF23 concentrations were measured on stored samples with three ELISAs. Setting: This study was conducted at subspecialty referral centers. Patients: Twenty-two patients with suspected TIO, 13 with confirmed tumors, were studied. Interventions: There were no interventions in this study. Main Outcome Measure: FGF23 concentration was the main outcome measure of this study. Results: Elevated FGF23 concentrations were detected using the Immunotopics C-terminal assay in 16 of 22 TIO patients (for a sensitivity of 73%), the Immunotopics Intact assay in five of 22 patients (sensitivity, 23%), and the Kainos Intact assay in 19 of 22 patients (sensitivity, 86%). In the 13 patients with confirmed tumors, the sensitivity was higher with all assays: 92% for the Immunotopics C-terminal assay, 38% for the Immunotopics Intact assay, and 100% for the Kainos assay. Conclusion: The Kainos Intact assay was the most sensitive, followed by the Immunotopics C-terminal assay. The findings of normal FGF23 concentrations in some patients with TIO may indicate that FGF 23 is not responsible for the hypophosphatemia in these patients or that FGF23 secretion by some tumors is partially responsive to serum phosphate. Normal FGF23 concentrations should be interpreted in relation to the serum phosphate and 1,25-dihydryxyvitamin-D concentrations.

Original languageEnglish
Pages (from-to)2055-2061
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number6
DOIs
StatePublished - 2006

Fingerprint

Tumors
Assays
Hypophosphatemia
Phosphates
Outcome Assessment (Health Care)
Neoplasms
Serum
Paraneoplastic Syndromes
Osteomalacia
fibroblast growth factor 23
Oncogenic osteomalacia
Muscular Diseases
Referral and Consultation
Enzyme-Linked Immunosorbent Assay
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. / Imel, Erik; Peacock, Munro; Pitukcheewanont, Pisit; Heller, Howard J.; Ward, Leanne M.; Shulman, Dorothy; Kassem, Moustapha; Rackoff, Paula; Zimering, Mark; Dalkin, Alan; Drobny, Elaine; Colussi, Giacomo; Shaker, Joseph L.; Hoogendoorn, Elizabeth H.; Hui, Siu; Econs, Michael.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 91, No. 6, 2006, p. 2055-2061.

Research output: Contribution to journalArticle

Imel, E, Peacock, M, Pitukcheewanont, P, Heller, HJ, Ward, LM, Shulman, D, Kassem, M, Rackoff, P, Zimering, M, Dalkin, A, Drobny, E, Colussi, G, Shaker, JL, Hoogendoorn, EH, Hui, S & Econs, M 2006, 'Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia', Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 6, pp. 2055-2061. https://doi.org/10.1210/jc.2005-2105
Imel, Erik ; Peacock, Munro ; Pitukcheewanont, Pisit ; Heller, Howard J. ; Ward, Leanne M. ; Shulman, Dorothy ; Kassem, Moustapha ; Rackoff, Paula ; Zimering, Mark ; Dalkin, Alan ; Drobny, Elaine ; Colussi, Giacomo ; Shaker, Joseph L. ; Hoogendoorn, Elizabeth H. ; Hui, Siu ; Econs, Michael. / Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. In: Journal of Clinical Endocrinology and Metabolism. 2006 ; Vol. 91, No. 6. pp. 2055-2061.
@article{fb4a11724e9a4655a6606b224ceb43f6,
title = "Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia",
abstract = "Context: Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome of hypophosphatemia, decreased renal phosphate reabsorption, normal or low serum 1,25-dihydryxyvitamin-D concentration, myopathy, and osteomalacia. Fibroblast growth factor 23 (FGF23) is a phosphaturic protein overexpressed in tumors that cause TIO and is, at least partly, responsible for the manifestations of TIO. Objective: The objective of this study was to determine the sensitivity of FGF23 measurements in TIO. Design: FGF23 concentrations were measured on stored samples with three ELISAs. Setting: This study was conducted at subspecialty referral centers. Patients: Twenty-two patients with suspected TIO, 13 with confirmed tumors, were studied. Interventions: There were no interventions in this study. Main Outcome Measure: FGF23 concentration was the main outcome measure of this study. Results: Elevated FGF23 concentrations were detected using the Immunotopics C-terminal assay in 16 of 22 TIO patients (for a sensitivity of 73{\%}), the Immunotopics Intact assay in five of 22 patients (sensitivity, 23{\%}), and the Kainos Intact assay in 19 of 22 patients (sensitivity, 86{\%}). In the 13 patients with confirmed tumors, the sensitivity was higher with all assays: 92{\%} for the Immunotopics C-terminal assay, 38{\%} for the Immunotopics Intact assay, and 100{\%} for the Kainos assay. Conclusion: The Kainos Intact assay was the most sensitive, followed by the Immunotopics C-terminal assay. The findings of normal FGF23 concentrations in some patients with TIO may indicate that FGF 23 is not responsible for the hypophosphatemia in these patients or that FGF23 secretion by some tumors is partially responsive to serum phosphate. Normal FGF23 concentrations should be interpreted in relation to the serum phosphate and 1,25-dihydryxyvitamin-D concentrations.",
author = "Erik Imel and Munro Peacock and Pisit Pitukcheewanont and Heller, {Howard J.} and Ward, {Leanne M.} and Dorothy Shulman and Moustapha Kassem and Paula Rackoff and Mark Zimering and Alan Dalkin and Elaine Drobny and Giacomo Colussi and Shaker, {Joseph L.} and Hoogendoorn, {Elizabeth H.} and Siu Hui and Michael Econs",
year = "2006",
doi = "10.1210/jc.2005-2105",
language = "English",
volume = "91",
pages = "2055--2061",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia

AU - Imel, Erik

AU - Peacock, Munro

AU - Pitukcheewanont, Pisit

AU - Heller, Howard J.

AU - Ward, Leanne M.

AU - Shulman, Dorothy

AU - Kassem, Moustapha

AU - Rackoff, Paula

AU - Zimering, Mark

AU - Dalkin, Alan

AU - Drobny, Elaine

AU - Colussi, Giacomo

AU - Shaker, Joseph L.

AU - Hoogendoorn, Elizabeth H.

AU - Hui, Siu

AU - Econs, Michael

PY - 2006

Y1 - 2006

N2 - Context: Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome of hypophosphatemia, decreased renal phosphate reabsorption, normal or low serum 1,25-dihydryxyvitamin-D concentration, myopathy, and osteomalacia. Fibroblast growth factor 23 (FGF23) is a phosphaturic protein overexpressed in tumors that cause TIO and is, at least partly, responsible for the manifestations of TIO. Objective: The objective of this study was to determine the sensitivity of FGF23 measurements in TIO. Design: FGF23 concentrations were measured on stored samples with three ELISAs. Setting: This study was conducted at subspecialty referral centers. Patients: Twenty-two patients with suspected TIO, 13 with confirmed tumors, were studied. Interventions: There were no interventions in this study. Main Outcome Measure: FGF23 concentration was the main outcome measure of this study. Results: Elevated FGF23 concentrations were detected using the Immunotopics C-terminal assay in 16 of 22 TIO patients (for a sensitivity of 73%), the Immunotopics Intact assay in five of 22 patients (sensitivity, 23%), and the Kainos Intact assay in 19 of 22 patients (sensitivity, 86%). In the 13 patients with confirmed tumors, the sensitivity was higher with all assays: 92% for the Immunotopics C-terminal assay, 38% for the Immunotopics Intact assay, and 100% for the Kainos assay. Conclusion: The Kainos Intact assay was the most sensitive, followed by the Immunotopics C-terminal assay. The findings of normal FGF23 concentrations in some patients with TIO may indicate that FGF 23 is not responsible for the hypophosphatemia in these patients or that FGF23 secretion by some tumors is partially responsive to serum phosphate. Normal FGF23 concentrations should be interpreted in relation to the serum phosphate and 1,25-dihydryxyvitamin-D concentrations.

AB - Context: Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome of hypophosphatemia, decreased renal phosphate reabsorption, normal or low serum 1,25-dihydryxyvitamin-D concentration, myopathy, and osteomalacia. Fibroblast growth factor 23 (FGF23) is a phosphaturic protein overexpressed in tumors that cause TIO and is, at least partly, responsible for the manifestations of TIO. Objective: The objective of this study was to determine the sensitivity of FGF23 measurements in TIO. Design: FGF23 concentrations were measured on stored samples with three ELISAs. Setting: This study was conducted at subspecialty referral centers. Patients: Twenty-two patients with suspected TIO, 13 with confirmed tumors, were studied. Interventions: There were no interventions in this study. Main Outcome Measure: FGF23 concentration was the main outcome measure of this study. Results: Elevated FGF23 concentrations were detected using the Immunotopics C-terminal assay in 16 of 22 TIO patients (for a sensitivity of 73%), the Immunotopics Intact assay in five of 22 patients (sensitivity, 23%), and the Kainos Intact assay in 19 of 22 patients (sensitivity, 86%). In the 13 patients with confirmed tumors, the sensitivity was higher with all assays: 92% for the Immunotopics C-terminal assay, 38% for the Immunotopics Intact assay, and 100% for the Kainos assay. Conclusion: The Kainos Intact assay was the most sensitive, followed by the Immunotopics C-terminal assay. The findings of normal FGF23 concentrations in some patients with TIO may indicate that FGF 23 is not responsible for the hypophosphatemia in these patients or that FGF23 secretion by some tumors is partially responsive to serum phosphate. Normal FGF23 concentrations should be interpreted in relation to the serum phosphate and 1,25-dihydryxyvitamin-D concentrations.

UR - http://www.scopus.com/inward/record.url?scp=33744956771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744956771&partnerID=8YFLogxK

U2 - 10.1210/jc.2005-2105

DO - 10.1210/jc.2005-2105

M3 - Article

C2 - 16551733

AN - SCOPUS:33744956771

VL - 91

SP - 2055

EP - 2061

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -